Willem-Jan Keune
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Willem-Jan Keune has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Nullin Divecha
Inositide Laboratory, School of Biological Sciences, University of Southampton, SO17 1BJ, Southampton, UK
9 shared publications David R. Jones
Oncology iMED, AstraZeneca, Alderley Park, Macclesfield SK10 4TF, UK
8 shared publicationsYvette Bultsma
Authors' Affiliations: 1The CRUK Inositide Laboratory; 2Breakthrough Breast Cancer Research Unit; 3Leukaemia Biology, Inositide Group Cancer Research UK Manchester Institute, The University of Manchester, Manchester; 4Applied Bioinformatics of Cancer, University of Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom; and 5Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Skåne University Hospital Malmö, Malmö, Sweden
6 shared publications- Anastassis Perrakis
The Netherlands Cancer Institute
5 shared publications - Allan John Bell Watson
EaStCHEM School of Chemistry University of St Andrews St Andrews UK
2 shared publications - Craig Jamieson
Pure and Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow, G1 1XL
2 shared publications
Latest Publications
- Open Access
Lysophosphatidic acid produced by Autotaxin acts as an allosteric modulator of its catalytic efficiency
Autotaxin is a secreted phosphodiesterase that converts lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA). LPA controls key cellular responses such as migration, proliferation and survival, implicating ATX-LPA signalling in various (patho)physiological processes and establishing it as a drug target. ATX structural and functional studies have revealed an orthosteric and an allosteric site, the “pocket” and the “tunnel”. Here, we revisit the kinetics of the ATX catalytic cycle in light of allosteric regulation, dissecting the different steps and pathways that lead to LPC hydrolysis. Consolidating all experimental kinetics data to a comprehensive catalytic model supported by molecular modelling simulations, suggests a positive feedback mechanism, regulated by the abundance of the LPA products activating hydrolysis of different LPC species. Our results complement and extend current understanding of ATX hydrolysis in light of the allosteric regulation by produced LPA species, and have implications for the design and application of orthosteric and allosteric ATX inhibitors.
Open AccessLysophosphatidic acid produced by Autotaxin acts as an allosteric modulator of its catalytic efficiency
Autotaxin is a secreted phosphodiesterase that converts lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA). LPA controls key cellular responses such as migration, proliferation and survival, implicating ATX-LPA signalling in various (patho)physiological processes and establishing it as a drug target. ATX structural and functional studies have revealed an orthosteric and an allosteric site, the “pocket” and the “tunnel”. Here, we revisit the kinetics of the ATX catalytic cycle in light of allosteric regulation, dissecting the different steps and pathways that lead to LPC hydrolysis. Consolidating all experimental kinetics data to a comprehensive catalytic model supported by molecular modelling simulations, suggests a positive feedback mechanism, regulated by the abundance of the LPA products activating hydrolysis of different LPC species. Our results complement and extend current understanding of ATX hydrolysis in light of the allosteric regulation by produced LPA species, and have implications for the design and application of orthosteric and allosteric ATX inhibitors.
- 16 February 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (5) , 2006-2017
Rational Design of Autotaxin Inhibitors by Structural Evolution of Endogenous Modulators
Autotaxin produces the bioactive lipid lysophosphatidic acid (LPA) and is a drug target of considerable interest for numerous pathologies. We report the expedient, structure-guided evolution of weak physiological allosteric inhibitors (bile salts) into potent competitive Autotaxin inhibitors that do not interact with the catalytic site. Functional data confirms that our lead compound attenuates LPA mediated signaling in cells and reduces LPA synthesis in vivo, providing a promising natural product derived scaffold for drug discovery.
- 16 February 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (5) , 2006-2017
Rational Design of Autotaxin Inhibitors by Structural Evolution of Endogenous Modulators
Autotaxin produces the bioactive lipid lysophosphatidic acid (LPA) and is a drug target of considerable interest for numerous pathologies. We report the expedient, structure-guided evolution of weak physiological allosteric inhibitors (bile salts) into potent competitive Autotaxin inhibitors that do not interact with the catalytic site. Functional data confirms that our lead compound attenuates LPA mediated signaling in cells and reduces LPA synthesis in vivo, providing a promising natural product derived scaffold for drug discovery.
- 5 January 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (2) , 722-748
Structure–Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode
Autotaxin (ATX) is a secreted enzyme responsible for the hydrolysis of lysophosphatidylcholine (LPC) to the bioactive lysophosphatidic acid (LPA) and choline. The ATX-LPA signaling pathway is implicated in cell survival, migration, and proliferation; thus, the inhibition of ATX is a recognized therapeutic target for a number of diseases including fibrotic diseases, cancer, and inflammation, among others. Many of the developed synthetic inhibitors for ATX have resembled the lipid chemotype of the native ligand; however, a small number of inhibitors have been described that deviate from this common scaffold. Herein, we report the structure–activity relationships (SAR) of a previously reported small molecule ATX inhibitor. We show through enzyme kinetics studies that analogues of this chemotype are noncompetitive inhibitors, and by using a crystal structure with ATX we confirm the discrete binding mode.
- 5 January 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (2) , 722-748
Structure–Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode
Autotaxin (ATX) is a secreted enzyme responsible for the hydrolysis of lysophosphatidylcholine (LPC) to the bioactive lysophosphatidic acid (LPA) and choline. The ATX-LPA signaling pathway is implicated in cell survival, migration, and proliferation; thus, the inhibition of ATX is a recognized therapeutic target for a number of diseases including fibrotic diseases, cancer, and inflammation, among others. Many of the developed synthetic inhibitors for ATX have resembled the lipid chemotype of the native ligand; however, a small number of inhibitors have been described that deviate from this common scaffold. Herein, we report the structure–activity relationships (SAR) of a previously reported small molecule ATX inhibitor. We show through enzyme kinetics studies that analogues of this chemotype are noncompetitive inhibitors, and by using a crystal structure with ATX we confirm the discrete binding mode.
- 1 August 2016
- Published by Elsevier in Journal of Structural Biology
- Vol. 195 (2) , 199-206
Structural snapshots of the catalytic cycle of the phosphodiesterase Autotaxin
- 1 August 2016
- Published by Elsevier in Journal of Structural Biology
- Vol. 195 (2) , 199-206
Structural snapshots of the catalytic cycle of the phosphodiesterase Autotaxin
- Open Access
- 14 April 2016
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 11248
Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling
Autotaxin (ATX) generates the lipid mediator lysophosphatidic acid (LPA). ATX-LPA signalling is involved in multiple biological and pathophysiological processes, including vasculogenesis, fibrosis, cholestatic pruritus and tumour progression. ATX has a tripartite active site, combining a hydrophilic groove, a hydrophobic lipid-binding pocket and a tunnel of unclear function. We present crystal structures of rat ATX bound to 7α-hydroxycholesterol and the bile salt tauroursodeoxycholate (TUDCA), showing how the tunnel selectively binds steroids. A structure of ATX simultaneously harbouring TUDCA in the tunnel and LPA in the pocket, together with kinetic analysis, reveals that bile salts act as partial non-competitive inhibitors of ATX, thereby attenuating LPA receptor activation. This unexpected interplay between ATX-LPA signalling and select steroids, notably natural bile salts, provides a molecular basis for the emerging association of ATX with disorders associated with increased circulating levels of bile salts. Furthermore, our findings suggest potential clinical implications in the use of steroid drugs.
- 14 April 2016
- Published by Springer Nature in Nature Communications
- Vol. 7 (1) , 11248
Open AccessSteroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling
Autotaxin (ATX) generates the lipid mediator lysophosphatidic acid (LPA). ATX-LPA signalling is involved in multiple biological and pathophysiological processes, including vasculogenesis, fibrosis, cholestatic pruritus and tumour progression. ATX has a tripartite active site, combining a hydrophilic groove, a hydrophobic lipid-binding pocket and a tunnel of unclear function. We present crystal structures of rat ATX bound to 7α-hydroxycholesterol and the bile salt tauroursodeoxycholate (TUDCA), showing how the tunnel selectively binds steroids. A structure of ATX simultaneously harbouring TUDCA in the tunnel and LPA in the pocket, together with kinetic analysis, reveals that bile salts act as partial non-competitive inhibitors of ATX, thereby attenuating LPA receptor activation. This unexpected interplay between ATX-LPA signalling and select steroids, notably natural bile salts, provides a molecular basis for the emerging association of ATX with disorders associated with increased circulating levels of bile salts. Furthermore, our findings suggest potential clinical implications in the use of steroid drugs.
- 1 June 2015
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1851 (6) , 898-910
PIP4K and the role of nuclear phosphoinositides in tumour suppression
- 1 June 2015
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
- Vol. 1851 (6) , 898-910
PIP4K and the role of nuclear phosphoinositides in tumour suppression
- 1 December 2013
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (23) , 6913-6925
Low PIP4K2B Expression in Human Breast Tumors Correlates with Reduced Patient Survival: A Role for PIP4K2B in the Regulation of E-Cadherin Expression
Phosphatidylinositol-5-phosphate (PtdIns5P) 4-kinase β (PIP4K2B) directly regulates the levels of two important phosphoinositide second messengers, PtdIns5P and phosphatidylinositol-(4,5)-bisphosphate [PtdIns(4,5)P2]. PIP4K2B has been linked to the regulation of gene transcription, to TP53 and AKT activation, and to the regulation of cellular reactive oxygen accumulation. However, its role in human tumor development and on patient survival is not known. Here, we have interrogated the expression of PIP4K2B in a cohort (489) of patients with breast tumor using immunohistochemical staining and by a meta-analysis of gene expression profiles from 2,999 breast tumors, both with associated clinical outcome data. Low PIP4K2B expression was associated with increased tumor size, high Nottingham histological grade, Ki67 expression, and distant metastasis, whereas high PIP4K2B expression strongly associated with ERBB2 expression. Kaplan–Meier curves showed that both high and low PIP4K2B expression correlated with poorer patient survival compared with intermediate expression. In normal (MCF10A) and tumor (MCF7) breast epithelial cell lines, mimicking low PIP4K2B expression, using short hairpin RNA interference-mediated knockdown, led to a decrease in the transcription and expression of the tumor suppressor protein E-cadherin (CDH1). In MCF10A cells, knockdown of PIP4K2B enhanced TGF-β–induced epithelial to mesenchymal transition (EMT), a process required during the development of metastasis. Analysis of gene expression datasets confirmed the association between low PIP4K2B and low CDH1expression. Decreased CDH1 expression and enhancement of TGF-β–induced EMT by reduced PIP4K2B expression might, in part, explain the association between low PIP4K2B expression and poor patient survival. Cancer Res; 73(23); 6913–25. ©2013 AACR.
- 1 December 2013
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (23) , 6913-6925
Low PIP4K2B Expression in Human Breast Tumors Correlates with Reduced Patient Survival: A Role for PIP4K2B in the Regulation of E-Cadherin Expression
Phosphatidylinositol-5-phosphate (PtdIns5P) 4-kinase β (PIP4K2B) directly regulates the levels of two important phosphoinositide second messengers, PtdIns5P and phosphatidylinositol-(4,5)-bisphosphate [PtdIns(4,5)P2]. PIP4K2B has been linked to the regulation of gene transcription, to TP53 and AKT activation, and to the regulation of cellular reactive oxygen accumulation. However, its role in human tumor development and on patient survival is not known. Here, we have interrogated the expression of PIP4K2B in a cohort (489) of patients with breast tumor using immunohistochemical staining and by a meta-analysis of gene expression profiles from 2,999 breast tumors, both with associated clinical outcome data. Low PIP4K2B expression was associated with increased tumor size, high Nottingham histological grade, Ki67 expression, and distant metastasis, whereas high PIP4K2B expression strongly associated with ERBB2 expression. Kaplan–Meier curves showed that both high and low PIP4K2B expression correlated with poorer patient survival compared with intermediate expression. In normal (MCF10A) and tumor (MCF7) breast epithelial cell lines, mimicking low PIP4K2B expression, using short hairpin RNA interference-mediated knockdown, led to a decrease in the transcription and expression of the tumor suppressor protein E-cadherin (CDH1). In MCF10A cells, knockdown of PIP4K2B enhanced TGF-β–induced epithelial to mesenchymal transition (EMT), a process required during the development of metastasis. Analysis of gene expression datasets confirmed the association between low PIP4K2B and low CDH1expression. Decreased CDH1 expression and enhancement of TGF-β–induced EMT by reduced PIP4K2B expression might, in part, explain the association between low PIP4K2B expression and poor patient survival. Cancer Res; 73(23); 6913–25. ©2013 AACR.
- 10 October 2013
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 455 (3) , 347-358
Collaboration of AMPK and PKC to induce phosphorylation of Ser413 on PIP5K1B resulting in decreased kinase activity and reduced PtdIns(4,5)P2 synthesis in response to oxidative stress and energy restriction
The spatial and temporal regulation of the second messenger PtdIns(4,5)P2 has been shown to be crucial for regulating numerous processes in the cytoplasm and in the nucleus. Three isoforms of PIP5K1 (phosphatidylinositol 4-phosphate 5-kinase), A, B and C, are responsible for the regulation of the major pools of cellular PtdIns(4,5)P2. PIP5K1B is negatively regulated in response to oxidative stress although it remains unclear which pathways regulate its activity. In the present study, we have investigated the regulation of PIP5K1B by protein phosphorylation. Using MS analysis, we identified 12 phosphorylation sites on PIP5K1B. We developed a phospho-specific antibody against Ser413 and showed that its phosphorylation was increased in response to treatment of cells with phorbol ester, H2O2 or energy restriction. Using inhibitors, we define a stress-dependent pathway that requires the activity of the cellular energy sensor AMPK (AMP-activated protein kinase) and PKC (protein kinase C) to regulate Ser413 phosphorylation. Furthermore, we demonstrate that PKC can directly phosphorylate Ser413in vitro. Mutation of Ser413 to aspartate to mimic serine phosphorylation decreased both PIP5K1B activity in vitro and PtdIns(4,5)P2 synthesis in vivo. Our studies show that collaboration between AMPK and PKC dictates the extent of Ser413 phosphorylation on PIP5K1B and regulates PtdIns(4,5)P2 synthesis.
- 10 October 2013
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 455 (3) , 347-358
Collaboration of AMPK and PKC to induce phosphorylation of Ser413 on PIP5K1B resulting in decreased kinase activity and reduced PtdIns(4,5)P2 synthesis in response to oxidative stress and energy restriction
The spatial and temporal regulation of the second messenger PtdIns(4,5)P2 has been shown to be crucial for regulating numerous processes in the cytoplasm and in the nucleus. Three isoforms of PIP5K1 (phosphatidylinositol 4-phosphate 5-kinase), A, B and C, are responsible for the regulation of the major pools of cellular PtdIns(4,5)P2. PIP5K1B is negatively regulated in response to oxidative stress although it remains unclear which pathways regulate its activity. In the present study, we have investigated the regulation of PIP5K1B by protein phosphorylation. Using MS analysis, we identified 12 phosphorylation sites on PIP5K1B. We developed a phospho-specific antibody against Ser413 and showed that its phosphorylation was increased in response to treatment of cells with phorbol ester, H2O2 or energy restriction. Using inhibitors, we define a stress-dependent pathway that requires the activity of the cellular energy sensor AMPK (AMP-activated protein kinase) and PKC (protein kinase C) to regulate Ser413 phosphorylation. Furthermore, we demonstrate that PKC can directly phosphorylate Ser413in vitro. Mutation of Ser413 to aspartate to mimic serine phosphorylation decreased both PIP5K1B activity in vitro and PtdIns(4,5)P2 synthesis in vivo. Our studies show that collaboration between AMPK and PKC dictates the extent of Ser413 phosphorylation on PIP5K1B and regulates PtdIns(4,5)P2 synthesis.
- 1 May 2013
- Published by Elsevier in Advances in Biological Regulation
- Vol. 53 (2) , 179-189
PtdIns5P and Pin1 in oxidative stress signaling
- 1 May 2013
- Published by Elsevier in Advances in Biological Regulation
- Vol. 53 (2) , 179-189
PtdIns5P and Pin1 in oxidative stress signaling
- Open Access
- 14 December 2012
- Published by Wiley in The FASEB Journal
- Vol. 27 (4) , 1644-1656
PtdIns5 P is an oxidative stress‐induced second messenger that regulates PKB activation
Oxidative stress initiates signaling pathways, which protect from stress‐induced cellular damage, initiate apoptosis, or drive cells into senescence or into tumorigenesis. Oxidative stress regulates the activity of the cell survival factor PKB, through the regulation of PtdIns(3,4,5) P 3 synthesis. Whether oxidative stress regulates other phosphoinositides to control PKB activation is not clear. Here we show that PtdIns5 P is a redox‐regulated second messenger. In response to hydrogen peroxide (H 2 O 2 ), we measured an increase in PtdIns5 P in cells derived from human osteosarcoma, U2OS (5‐fold); breast tumors, MDA‐MB‐468 (2‐fold); and fibrosarcoma, HT1080 (3‐fold); and in p53‐null murine embryonic fibroblasts (8‐fold). In U2OS cells, the increase in H 2 O 2 ‐dependent PtdIns5 P did not require mTOR, PDK1, PKB, ERK, and p38 signaling or PIKfyve, a lipid kinase that increases PtdIns5 P in response to osmotic and oncogenic signaling. A reduction in H 2 O 2 ‐in‐duced PtdIns5 P levels by the overexpression of PIP4K revealed its role in PKB activation. Suppression of H 2 O 2 ‐induced PtdIns5 P generation reduced PKB activation and, surprisingly, reduced cell sensitivity to growth inhibition by H 2 O 2 . These data suggest that inhibition of PIP4K signaling might be useful as a novel strategy to increase the susceptibility of tumor cells to therapeutics that function through increased oxidative stress.—Jones, D. R., Foulger, R., Keune, W.‐J., Bultsma, Y., Divecha, N. PtdIns5 P is an oxidative stress‐induced second messenger that regulates PKB activation. FASEB J. 27, 1644–1656 (2013). www.fasebj.org
- 14 December 2012
- Published by Wiley in The FASEB Journal
- Vol. 27 (4) , 1644-1656
Open AccessPtdIns5 P is an oxidative stress‐induced second messenger that regulates PKB activation
Oxidative stress initiates signaling pathways, which protect from stress‐induced cellular damage, initiate apoptosis, or drive cells into senescence or into tumorigenesis. Oxidative stress regulates the activity of the cell survival factor PKB, through the regulation of PtdIns(3,4,5) P 3 synthesis. Whether oxidative stress regulates other phosphoinositides to control PKB activation is not clear. Here we show that PtdIns5 P is a redox‐regulated second messenger. In response to hydrogen peroxide (H 2 O 2 ), we measured an increase in PtdIns5 P in cells derived from human osteosarcoma, U2OS (5‐fold); breast tumors, MDA‐MB‐468 (2‐fold); and fibrosarcoma, HT1080 (3‐fold); and in p53‐null murine embryonic fibroblasts (8‐fold). In U2OS cells, the increase in H 2 O 2 ‐dependent PtdIns5 P did not require mTOR, PDK1, PKB, ERK, and p38 signaling or PIKfyve, a lipid kinase that increases PtdIns5 P in response to osmotic and oncogenic signaling. A reduction in H 2 O 2 ‐in‐duced PtdIns5 P levels by the overexpression of PIP4K revealed its role in PKB activation. Suppression of H 2 O 2 ‐induced PtdIns5 P generation reduced PKB activation and, surprisingly, reduced cell sensitivity to growth inhibition by H 2 O 2 . These data suggest that inhibition of PIP4K signaling might be useful as a novel strategy to increase the susceptibility of tumor cells to therapeutics that function through increased oxidative stress.—Jones, D. R., Foulger, R., Keune, W.‐J., Bultsma, Y., Divecha, N. PtdIns5 P is an oxidative stress‐induced second messenger that regulates PKB activation. FASEB J. 27, 1644–1656 (2013). www.fasebj.org